Italy's Newron has raised $99 million in its IPO as its researchers advance therapies for pain and Parkinson's disease. Newron priced its shares at 55 Swiss francs, on the upper end of its 45 to 60 franc range. Newron's two top drug hopes--safinamide and ralfinamide--both have the potential to reach blockbuster status with more than a billion dollars in annual revenue.
- here's the AFX report on the IPO